NEWS
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
ZyVersa Therapeutics (ZVSA) has chosen obesity and related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100. This decision is based on the growing global obesity drug market, which reached $24 billion in 2023 and is forecasted to reach up to $131 billion by 2028. Obesity affects over 40% of Americans and is associated with multiple chronic conditions, costing over $1.4 trillion annually in the US.
ZyVersa believes that IC 100, which inhibits multiple types of inflammasomes, could complement GLP-1 agonists by addressing chronic tissue inflammation not targeted by current treatments. The company plans to submit an Investigational New Drug (IND) application in Q4-2024, with Phase 1 clinical trials to follow. Preclinical collaborations are underway to assess IC 100's potential in treating atherosclerosis and obesity-related metabolic syndrome.
ZyVersa believes that IC 100, which inhibits multiple types of inflammasomes, could complement GLP-1 agonists by addressing chronic tissue inflammation not targeted by current treatments. The company plans to submit an Investigational New Drug (IND) application in Q4-2024, with Phase 1 clinical trials to follow. Preclinical collaborations are underway to assess IC 100's potential in treating atherosclerosis and obesity-related metabolic syndrome.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1692Followers
93Following
13KVisitors
Follow